293 related articles for article (PubMed ID: 26384117)
1. Fecal pyruvate kinase is not suitable for discrimination between inflammatory bowel disease exacerbation and acute gastroenteritis.
Czub E; Nowak JK; Moczko J; Mankowski P; Lisowska A; Banaszkiewicz A; Banasiewicz T; Walkowiak J
Dev Period Med; 2015; 19(2):167-73. PubMed ID: 26384117
[TBL] [Abstract][Full Text] [Related]
2. Comparison of fecal pyruvate kinase isoform M2 and calprotectin in assessment of pediatric inflammatory bowel disease severity and activity.
Czub E; Nowak JK; Szaflarska-Poplawska A; Grzybowska-Chlebowczyk U; Landowski P; Moczko J; Adamczak D; Mankowski P; Banasiewicz T; Plawski A; Walkowiak J
Acta Biochim Pol; 2014; 61(1):99-102. PubMed ID: 24649481
[TBL] [Abstract][Full Text] [Related]
3. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation.
Chung-Faye G; Hayee B; Maestranzi S; Donaldson N; Forgacs I; Sherwood R
Inflamm Bowel Dis; 2007 Nov; 13(11):1374-8. PubMed ID: 17577247
[TBL] [Abstract][Full Text] [Related]
4. Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease.
Czub E; Herzig KH; Szaflarska-Popawska A; Kiehne K; Socha P; Woś H; Kamińska B; Błaszczyński M; Cichy W; Bała G; Brodzicki J; Grzybowska-Chlebowczyk U; Walkowiak J
Scand J Gastroenterol; 2007 Oct; 42(10):1147-50. PubMed ID: 17852864
[TBL] [Abstract][Full Text] [Related]
5. The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity.
Lee YW; Lee KM; Lee JM; Chung YY; Kim DB; Kim YJ; Chung WC; Paik CN
Korean J Intern Med; 2019 Jan; 34(1):72-80. PubMed ID: 29347813
[TBL] [Abstract][Full Text] [Related]
6. Comparison of a novel fecal marker--fecal tumor pyruvate kinase type M2 (M2-PK) with fecal calprotectin in patients with inflammatory bowel disease: a prospective study.
Shastri YM; Povse N; Schröder O; Stein J
Clin Lab; 2008; 54(9-10):389-90. PubMed ID: 19097497
[No Abstract] [Full Text] [Related]
7. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.
Kaiser T; Langhorst J; Wittkowski H; Becker K; Friedrich AW; Rueffer A; Dobos GJ; Roth J; Foell D
Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327
[TBL] [Abstract][Full Text] [Related]
8. Fecal Matrix Metalloprotease-9 and Lipocalin-2 as Biomarkers in Detecting Endoscopic Activity in Patients With Inflammatory Bowel Diseases.
Buisson A; Vazeille E; Minet-Quinard R; Goutte M; Bouvier D; Goutorbe F; Pereira B; Barnich N; Bommelaer G
J Clin Gastroenterol; 2018 Aug; 52(7):e53-e62. PubMed ID: 28723856
[TBL] [Abstract][Full Text] [Related]
9. Comparison of fecal pyruvate kinase isoform M2 and calprotectin in acute diarrhea in hospitalized children.
Czub E; Nowak JK; Moczko J; Lisowska A; Banaszkiewicz A; Banasiewicz T; Walkowiak J
Sci Rep; 2014 Apr; 4():4769. PubMed ID: 24759699
[TBL] [Abstract][Full Text] [Related]
10. Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: a diagnostic accuracy meta-analysis.
Rokkas T; Portincasa P; Koutroubakis IE
J Gastrointestin Liver Dis; 2018 Sep; 27(3):299-306. PubMed ID: 30240474
[TBL] [Abstract][Full Text] [Related]
11. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Kandala NB; Shyangdan D; Arasaradnam R; Clar C; Johnston R
Health Technol Assess; 2013 Nov; 17(55):xv-xix, 1-211. PubMed ID: 24286461
[TBL] [Abstract][Full Text] [Related]
12. Comparison of three commercial fecal calprotectin ELISA test kits used in patients with Inflammatory Bowel Disease.
Mirsepasi-Lauridsen HC; Bachmann Holmetoft U; Ingdam Halkjær S; Angeliki Krogfelt K; Munk Petersen A
Scand J Gastroenterol; 2016; 51(2):211-7. PubMed ID: 26359672
[TBL] [Abstract][Full Text] [Related]
13. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
[TBL] [Abstract][Full Text] [Related]
14. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome.
Sydora MJ; Sydora BC; Fedorak RN
J Crohns Colitis; 2012 Mar; 6(2):207-14. PubMed ID: 22325175
[TBL] [Abstract][Full Text] [Related]
15. Fecal Calprotectin as an Activity Marker of Inflammatory Bowel Disease in Children.
Krzesiek E
Adv Clin Exp Med; 2015; 24(5):815-22. PubMed ID: 26768632
[TBL] [Abstract][Full Text] [Related]
16. Rapid fecal calprotectin test for prediction of mucosal inflammation in ulcerative colitis and Crohn disease: a prospective cohort study.
Moniuszko A; Głuszek S; Rydzewska G
Pol Arch Intern Med; 2017 May; 127(5):312-318. PubMed ID: 28442699
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of a novel and rapid assay system for fecal calprotectin in pediatric patients with inflammatory bowel diseases.
Inoue K; Aomatsu T; Yoden A; Okuhira T; Kaji E; Tamai H
J Gastroenterol Hepatol; 2014; 29(7):1406-12. PubMed ID: 24635100
[TBL] [Abstract][Full Text] [Related]
18. Elevated fecal M2-pyruvate kinase in children with cystic fibrosis: a clue to the increased risk of intestinal malignancy in adulthood?
Pang T; Leach ST; Katz T; Jaffe A; Day AS; Ooi CY
J Gastroenterol Hepatol; 2015 May; 30(5):866-71. PubMed ID: 25376228
[TBL] [Abstract][Full Text] [Related]
19. Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.
Puolanne AM; Kolho KL; Alfthan H; Ristimäki A; Mustonen H; Färkkilä M
Dig Dis Sci; 2017 Nov; 62(11):3123-3130. PubMed ID: 28948412
[TBL] [Abstract][Full Text] [Related]
20. Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease.
Hoekman DR; Diederen K; Koot BG; Tabbers MM; Kindermann A; Benninga MA
Eur J Pediatr; 2016 Oct; 175(10):1335-42. PubMed ID: 27573259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]